[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thc":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,73,101,130,153,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100601050","thc-titration-of-high-potency-cannabis-concentrates-100601050",false,"NCT07105449","THC Titration of High-Potency Cannabis Concentrates","THC Titration of High-Potency Cannabis Concentrates: A Randomized Cross-Over Trial","THC Titration","Inclusion Criteria:\n\n* Age 19-55 years.\n* Frequency of primary exposure to cannabis 1-4 occasions per week, through any route of administration, over the past three months; participants must report experience with vaping high-potency liquid concentrates with more than 3 exposures to 90% THC and willingness to use such products in the study.\n* Refrain from cannabis for 48 hours and from alcohol for 12 hours before visits.\n* Agree not to drive a car for 24 hours after each visit.\n* Abstain from recreational drugs for at least 48 hours prior to each visit.\n* Abstain from any drugs not medically required.\n* Well-controlled blood pressure for participants with hypertension.\n\nExclusion Criteria:\n\n* Pregnant\u002Fbreastfeeding (women of childbearing potential must have a negative pregnancy test and report use of appropriate contraception).\n* Evidence of cardiac arrhythmias\u002Ffailure, ischaemic heart disease.\n* Recent open heart\u002Fopen chest surgery or cataract surgery.\n* Evidence from Structured Clinical Interview for DSM-5 \\[SCID-5-CT\\] or clinical evaluation of lifetime psychotic disorder\u002Fschizophrenia or bipolar disorder; family history of a first-degree relative with a diagnosis of psychotic disorder or schizophrenia; history of psychiatric co-morbidities in the past year (major depression, anxiety disorder or suicide attempt in past year or current suicidal ideation) and current substance use disorder\u002Fdependence.\n* Evidence of neurological illness (e.g., stroke, epilepsy, traumatic brain injury).\n* Renal or hepatic abnormalities (self-report and blood hematology\u002Fchemistry); and\n* Respiratory diseases, including asthma and physician-diagnosed lung disease.\n* Taking prescribed medications that contain either THC or cannabidiol (CBD).\n* Participation in another clinical or non-therapeutic study in the last three months.\n* Bleeding disorders.",true,"ALL","19 Years","55 Years",{"count":22,"type":23},48,"ESTIMATED","INTERVENTIONAL",[26],"NA","High-potency cannabis use is associated with public health risks, such as cannabis use disorder, psychotic disorders, and impaired cognition. Legal markets in the US and Canada are geared towards the commercialization of high-tetrahydrocannabinol (THC) products, including concentrates as high as 90-95%. The cannabis industry has resisted regulation of higher-potency products claiming that cannabis consumers naturally self-titrate their use, but the limited evidence to date suggests that even though consumers may use less cannabis as potency rises, consuming higher potency products still leads to greater THC consumption. The investigators will use a randomized crossover trial to evaluate the ability of 36 regular cannabis consumers (18 females and 18 males) to self-titrate the THC dose when vaping concentrates to achieve the desired psychoactive effects. The investigators will also characterize and compare the subjective, cognitive, physiological, and pharmacokinetic effects between cannabis concentrates of different potencies (30%, 60%, and 90% THC). Working with US scientists, the setting of this study will be Toronto, Canada, in the context of federal legalization of cannabis, unique access to cannabis products not available in the US for research purposes, and an encouraging regulatory environment. The investigators will test commercial products that are representative of the THC ranges available in the legal market. Aim 1: To evaluate the ability of regular cannabis consumers to self-titrate their THC dose when vaping concentrates of different potencies. The investigators will compare markers of titration (biological: THC blood levels; behavioral: inhalation topography; subjective: self-reported levels of intoxication) over a range of potencies for a comprehensive characterization of titration practice. The investigators hypothesize that participants will be able to partially but not proportionally reduce THC intake with increase in THC potency. In other words, the investigators anticipate that the proportional decrease in blood THC levels will be lower than the proportional increase in THC concentrations. Aim 2: To compare the cognitive impairment, physiological effects, and addiction liability of consuming lower versus higher THC potency concentrates. The investigators hypothesize that cognitive impairment and physiological effects will be less pronounced with lower-THC concentrates in a dose-response fashion. The investigators will also explore differences in addiction liability between potencies as higher THC concentrations may result in greater dysphoric reactions. These acute effects may be related to long term harms such as accidents, CVD events, and CUD. Exploratory Aim: To explore sex differences in titration efficiency, blood THC concentrations, cognitive impairment, physiological effects, and addiction liability. The investigators propose to analyze sex differences in our primary and secondary outcomes (e.g., whether females will be able to titrate more efficiently than males). This experimental evidence will provide data on the potential acute harms related to concentrates and inform policy decisions on the need to decrease access and\u002For prevent their initiation and implement information and education campaigns to increase awareness on the risks of using them.",[29],"THC",[31,32,33,34,35,29],"Cannabis","THC Concentrates","Self-Titration","Subjective Effects","Cognition","RECRUITING","2026-06-09",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":40},"2025-10-01",{"date":44,"type":23},"2028-09-30",{"name":46,"class":47},"Centre for Addiction and Mental Health","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":20,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":48},"100545212","phase-1-behavioral-pharmacology-of-orally-administered-thc-and-d-limonene-100545212","NCT06378957","Behavioral Pharmacology of Orally Administered THC and D-limonene","Inclusion Criteria:\n\n* Have provided written informed consent\n* Be between the ages of 21 and 55\n* Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests\n* Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission\n* Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission.\n* Have a body mass index (BMI) in the range of 18 to 36 kg\u002Fm2\n* Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg\n* Have no allergies to any of the ingredients used to prepare (cellulose, THC, d-limonene).\n* Report having used a high THC cannabis product in the past 3 years and having experienced anxiety after consuming cannabis at least once in lifetime.\n\nExclusion Criteria:\n\n* Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit;\n* History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.\n* Use of an over the counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.\n* Use of a prescription medication (with the exception of birth control prescriptions) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.\n* Average use of cannabis more than 2 times per week in the prior 3 months.\n* History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).\n* Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.\n* Individuals with anemia or who have donated blood in the prior 30 days","21 Years",{"count":57,"type":23},65,[59],"PHASE1","The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.",[62,29,63],"Subjective Drug Effects","D-limonene","2026-05-27",{"date":66,"type":40},"2026-05-28",{"date":68,"type":40},"2025-02-14",{"date":70,"type":23},"2027-12-31",{"name":72,"class":47},"Johns Hopkins University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":48},"100478816","phase-2-effects-of-cannabidiol-and-tetrahydrocannabinol-on-microbiome-and-neuroinflammation-in-hiv-100478816","NCT05514899","Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV","Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids, and Neuroinflammation in HIV","CAMI","1. Aged 21 to 70 years old\n2. Possess the capacity to provide informed consent to a set of neuromedical assessment procedures.\n3. Experience with cannabis use at least once in the past 5 years without major adverse effects (e.g., psychosis, syncope)\n4. No or low cannabis use in the past 2 weeks, defined as no cannabis exposure or use or use limited to only once in the past 2 weeks.\n5. Willing to abstain from use of cannabis, CBD, THC, or synthetic cannabinoids outside the study during the 6-week intervention\n6. Individuals with HIV must meet the following criteria\n\n   1. Virally suppressed on stable ART for at least 6 months and have no more than 1 prior event of virologic failure (i.e., required change in ARTs due to virologic failure)\n   2. Stage 1 or 2 infection\n   3. Have a \"normal\" CD4 count defined as ≥350 cells\u002Fmicroliter\n   4. No significant history of ART regimen adherence challenges\n7. Ability to adhere to the study visit schedule.\n\nExclusion Criteria:\n\n1. Exclusion criteria will be: any substance use disorder (abuse or dependence) other than cannabis in the last 30 days;\n2. Significant cognitive impairment such as Dementia, including Alzheimer's disease\n3. Pregnancy or lactation, or unwillingness to prevent pregnancy during the trial; refusal to maintain highly effective contraceptive methods (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner) during the study for persons of child-bearing potential or those with partners of child-bearing potential\n4. Evidence of moderately or worse compromised liver or kidney function, including moderate (Child-Hugh B) or severe (Child-Hugh C) hepatic impairment and AST and ALT above ULN and total bilirubin above ULN;\n5. Evidence of significant cardiovascular risk, resting heart rate \\\u003C50 or \\>110 beats per minute, uncontrolled hypertension (systolic blood pressure \\\u003C80 or \\>140 mmHg; diastolic blood pressure \\\u003C50 or \\>90 mmHg), history of myocardial infarction, congestive heart failure, or arrhythmia);\n6. Evidence of chronic pulmonary disease requiring supplemental oxygen;\n7. Active, recent, or remote medical history of hepatobiliary-related illness, including elevated transaminase levels above 3 times the upper limit of normal accompanied by elevations in total bilirubin above 2 times the upper limit of normal at screening;\n8. Insulin dependent diabetics\n9. Allergy to the study drugs or any of their constituents including sesame\n10. Use of medications with absolute contraindicated or potential significant interactions\n11. Use of sedating medications\n12. Weighing less than 60 kg at screening to minimize the risk of elevated transaminases as a result of exposure to cannabidiol;\n13. Active, uncontrolled psychiatric disorder with psychotic features, severe depression, or suicidality; Participants will be excluded if they have had a history of suicide attempt, recent suicidal ideation or behavior as indexed by their Beck Depression Inventory-II (BDI-II) score is greater than or equal to 29 (severe depression).\n14. Neurologic disorder that could compromise interpretation of study findings, including uncontrolled seizure disorder (active seizures within the past 3 months), multiple sclerosis, Parkinson's disease, Alzheimer's disease, and recent (past 3 months) cerebral infarction or hemorrhage with neurological sequelae.","70 Years",{"count":83,"type":23},90,[85],"PHASE2","This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures designed to monitor subject safety and measure the effects of the study drug.",[88,31,29,89,90,91],"HIV","Neuroinflammatory Disease","Neuroinflammatory Response","Microbiome","2026-04-27",{"date":94,"type":40},"2026-05-01",{"date":96,"type":40},"2023-09-01",{"date":98,"type":23},"2027-10-31",{"name":100,"class":47},"University of California, San Diego",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":110,"briefSummary":111,"conditions":112,"keywords":117,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":48},"100516043","phase-2-understanding-the-clinical-pharmacology-of-marijuana-tobacco-co-administration-100516043","NCT05999383","Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration","CANNIC","Inclusion Criteria:\n\n* Heart rate \\\u003C 105 beats per minute (BPM)\\*\n* Systolic Blood Pressure \\\u003C 160 and \\> 90\\*\n* Diastolic Blood Pressure \\\u003C 100 and \\> 50\\*\n\n  \\*Considered out of range if both machine and manual readings are above\u002Fbelow these thresholds.\n* Body Mass Index (BMI) ≤ 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues)\n* Current regular user of cannabis who smokes or vapes cannabis or THC extracts at least three days a week for the past 3 months or more\n* Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use\n* Current user of inhaled forms of tobacco\u002Fnicotine (cigarette, cigars, e-cigarettes) who use the product daily for the past 3 months or more\n* Saliva cotinine ≥ 30 ng\u002FmL\n\nExclusion Criteria:\n\n* Unstable medical conditions:\n\n  * Heart disease\n  * Seizures\n  * Cancer\n  * Thyroid disease (okay if controlled with medication)\n  * Diabetes\n  * Hepatitis B or C or Liver disease\n  * Glaucoma\n  * Kidney disease or urinary retention\n  * An ulcer in the past year\n  * Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)\n* Hypertension if uncontrolled (meaning participant has a diagnosis, but they are not taking medication\u002Funder treatment (e.g., diet or exercise plan)\n* Drug\u002FAlcohol Dependence\n\n  * Alcohol or illicit drug dependence within the past 12 months (currently in treatment) with the exception of those who recently completed an alcohol\u002Fdrug treatment program\n  * Positive toxicology test at the screening visit (THC \\& prescribed medications okay)\n  * Opioid replacement therapy (including methadone, buprenorphine, or other)\n* Psychiatric conditions\n\n  * Current or past schizophrenia, and\u002For current or past bipolar disorder\n  * Major depression, current or within the past year\n  * Major personality disorder\n  * Participants with current or past minor or moderate depression and\u002For anxiety disorders will be reviewed by the PI \\[study physician\\] and considered for inclusion\n  * History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per PI's \\[study physician's\\] approval\n* Current regular use of any psychiatric medications with the exception of Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate\n* Congenital or acquired immunodeficiency disorders (i.e. HIV, congenital immune deficiency syndrome, chronic diseases)\n* Other disorders (i.e. ICU, malnutrition, immunosuppressive therapy)\n* Traumatic brain injury\n* Recent onset or change (worsening) in cough, fever and\u002For abdominal symptoms (vomiting or pain) in the past two weeks\n* Medications\n\n  * Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs)\n  * Concurrent use of nicotine-containing medications\n  * Any stimulant medications (ex. Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment\n* Other\u002FMisc. Chronic Health Problems\n\n  * Oral thrush\n  * Fainting\n  * Other \"life threatening illnesses\" as per study physician's discretion\n* Pregnancy\n\n  * Pregnancy (self-reported and urine pregnancy test)\n  * Breastfeeding (determined by self-report)\n* Concurrent participation in another clinical trial\n* Inability to communicate in English\n* History of marijuana-induced psychosis or paranoia after smoking marijuana\n* Scoring a 7 or higher on the Severity of Dependence Scale (SDS) for cannabis use\n* Planning to quit smoking or vaping within the next 60 days\n* Planning to quit cannabis use within the next 60 days\n* Uncomfortable with getting blood drawn\n* Willingness to abstain from tobacco smoking and all combustible products for 13 hours before admission\n* Willingness to abstain from smoking\u002Fingestion of cannabis 13 hours before\n* Willingness to abstain from nicotine products 13 hours before each admission","65 Years",{"count":22,"type":23},[85],"This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.",[29,31,113,114,115,116],"Cannabis Use","Cannabis Smoking","Tobacco Use","Vaping",[29,31,118,119,120],"Marijuana","Nicotine","Vape","2026-01-05",{"date":123,"type":40},"2026-01-07",{"date":125,"type":40},"2025-07-01",{"date":127,"type":23},"2028-02-01",{"name":129,"class":47},"University of California, San Francisco",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":48},"100523721","phase-1-modulation-of-thc-effects-by-cbd-a-dose-ranging-study-100523721","NCT06099379","Modulation of THC Effects by CBD: a Dose-ranging Study","Modulation of ∆9-tetrahydrocannabinol Acute Psychoactive Effects by Ranging Doses of Cannabidiol in Healthy, Occasional Cannabis Users: a Controlled, Triple Blind, Randomized, Cross-over Study","SPECTRE","Inclusion Criteria:\n\n1. Between 21 and 49 years of age, inclusively;\n2. Have used cannabis at least once in their lifetime and have used cannabis three days or less in the 30 days prior to enrollment;\n3. Be able to provide a signed informed consent;\n4. Willing to comply with study procedures and requirements as per protocol;\n5. Have a forced expiratory volume in first second (FEV) less than or equal to 90 %;\n6. Able to communicate and understand English or French language;\n7. For female participants:\n\n   a. No childbearing potential, defined as: i. postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or ii. Documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or b. For female of childbearing potential: i. Must have negative pregnancy test result at screening and at subsequent visits.\n\nii. AND have no pregnancy plan while on the study iii. AND must agree to use a medically accepted method of birth control throughout the study.\n\nExclusion criteria\n\nParticipants will be excluded if any of the following criteria are met:\n\n1. Any disabling medical condition, as assessed by medical history, physical exam, vital signs and\u002For laboratory assessments that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent;\n2. Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or current suicidality based on the Mini International Neuropsychiatric Interview);\n3. Any other disabling, unstable or acute mental condition that, in the opinion of the study physician, precludes safe participation in the study or ability to provide fully informed consent;\n4. Known chronic liver disease or aspartate transaminase\u002Falanine transaminase (AST\u002FALT) two times higher than upper limit of normal values at screening visit;\n5. Blood pressure higher than 130\u002F80 mmHg;\n6. Kidney disorders;\n7. Bleeding disorders;\n8. Current moderate or severe DSM-5 substance use disorder (except nicotine) according to SCID-V;\n9. Currently pregnant, breastfeeding or planning to become pregnant either at screening or while enrolled in the study;\n10. Pending legal action or other reason that, in the opinion of the study physician, might prevent study completion;\n11. Use of medication within 7 days of experimental sessions; which, in the opinion of the Investigator, may interact with cannabis.\n12. Participation in clinical studies or undergoing other investigational procedure involving cannabis or cannabinoids administration within 30 days prior to randomization.\n13. Resting heart rate over 100 beats per minute.\n14. Current body mass index (BMI) over 29.9 kg\u002Fm2.\n15. Any clinically significant electrocardiogram abnormalities at screening visit.","49 Years",{"count":140,"type":23},100,[59,85],"The purposes of this study are 1) to determine if CBD modulates THC-induced acute psychoactive effects at different CBD:THC ratios, compared with the control product (0:20, 20:20, 40:20, 80:20, 120:20) and 2) to determine if different doses of CBD modulate other THC induced behavioral effects, compared with the control product and 3)To explore qualitatively whether CBD modulates THC effects by mechanisms that are not detected with standard clinical research tools.",[31,29],"2025-12-16",{"date":146,"type":40},"2025-12-22",{"date":148,"type":40},"2024-06-27",{"date":150,"type":23},"2026-12-31",{"name":152,"class":47},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":18,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":24,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":48},"100565849","phase-2-pilot-fmri-studies-of-aging-related-effects-of-thc-100565849","NCT06647524","Pilot fMRI Studies of Aging-Related Effects of THC","Inclusion Criteria:\n\n* CNB use within past 2 years and felt \"high\" when used.\n* Able to read, speak, and understand English.\n* Able and willing to provide written informed consent, and willing to commit to the study protocol.\n\nExclusion Criteria:\n\n* Current marijuana tolerance, desire to cut down, or cravings to use during periods of abstinence.\n* Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment\n* History of adverse effects with CNB\n* CNB users who are abstaining\n* IQ \\\u003C80 on the Wechsler Abbreviated Scale of Intelligence\n* Inability to comprehend written instructions using the WRAT 4 reading achievement test\n* Pregnant, breastfeeding, and ineffective birth control methods\n* Unable or unsafe to have an MRI\n* Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy\n* History of head trauma with loss of consciousness \\> 30 minutes or concussion lasting 30 days\n* Focal brain lesion seen on structural MRI\n* Any medical\u002Fneurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome)\n* Anyone deemed unsafe to study personnel for any reason\n* Hearing loss such that subject cannot hear sounds at the levels (dB) or pitches (Hz) to be used in the study\n* Significant pain and\u002For reduced mobility in the arms","18 Years","75 Years",{"count":162,"type":23},10,[85],"The purpose of this study is to begin investigating acute impairment of various forms of memory and learning by Tetrahydrocannabinol (THC) in cannabis (CNB) compared to placebo, in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design in young to middle-aged adults.",[29],[167,168],"Memory Impairment","Learning Impairment","2025-10-06",{"date":171,"type":40},"2025-10-09",{"date":125,"type":40},{"date":174,"type":23},"2027-12",{"name":176,"class":47},"Yale University",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":108,"enrollmentInfo":184,"targetDuration":4,"studyType":24,"phases":186,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":48},"100488565","phase-2-multimodal-magnetoencephalography-and-electroencephalography-exploration-of-the-acute-effects-of-thc-exposure-on-neural-noise-and-information-transmission-within-working-memory-networks-100488565","NCT05641766","Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks","THC-MEG","Inclusion Criteria:\n\n* Cannabis use at least once in the past 12 months\n* No cannabis use during the course of the study confirmed with negative urine toxicology at screening and on each test day\n* Good physical and mental health\n\nExclusion Criteria:\n\n* Cannabis naïve individuals\n* Lifetime or current medical, psychiatric or psychosocial disorders or history that is deemed unsuitable for participation in the study per PI discretion.\n* Positive pregnancy test, lactation, or refusal to practice birth control for the duration of the study and for two weeks following completion\n* Major current or recent stressors\n* Positive urine drug test\n* Contraindication for Magnetic Resonance Imaging\n* Treatment with psychotropic medication as per discretion of the PI\n* IQ less than 80\n* Weight exceeding 166kg\n* Diagnosis of major psychotic or manic disorder in first-degree relatives.",{"count":185,"type":23},50,[85],"The purpose of this study is to use non-invasive brain imaging methods (MEG and EEG) to characterize the effects of THC on brain activity during learning.",[29],[190,191,29,192,193,194,195],"MEG","EEG","Placebo","Working Memory","Neural Noise","Cognitive Process","NOT_YET_RECRUITING","2025-06-04",{"date":199,"type":40},"2025-06-10",{"date":201,"type":23},"2025-08-31",{"date":203,"type":23},"2025-12-01",{"name":176,"class":47}]